Pump and dump. Buyer beware of $YFRM. Paid promotion to help CEO dilute massive amounts of shares courtesy of your wallets!!
YFRM ~ Is Ready to Breakout today on the Charts and there is Big anticipation of a Run in YFRM shares this week. YFRM ~ Releases 3 Releases 3 'Stem Cell' proprietary documents (trading at only .0869 cents right now). YFRM is our new Stem Cell Biotech pick with great upside potential. We are initiating strong coverage on YFRM this Morning and feel this wallstreet gem of a play has bottomed and is ready for a Strong run to the upside short term.
YFRM has bottomed last week around the .08 cent range and is trading above its 50 day moving average at .079 cents. YFRM is a New & Hot Stem Cell play we feel has good potential for trading down here at these low levels and off the recent bottom/bounce. YFRM looks to be a super Wallstreet gem for trading this week now that it has bottomed and has been way oversold on the charts. This coupled with the recent big news tells us there is Great Short term potential here Members. This is one you are NOT going to want to miss so get ready today so you can take advantage of YFRM for Monday's Trading session as there is already huge anticipation for YFRM. YFRM has been releasing some pretty big news in the market with ISCI and we feel this is one has great short term trading potential.
YFRM ~News is out Premarket~
YaFarm Technologies Announces ISCI Release of Patient Publications
PITTSTON, ME--(Mar 4, 2013) - YaFarm Technologies, Inc. ( YFRM ) (YaFarm, or the Company) is pleased to announce the Integrative Stem Cell Institute (ISCI) has released three proprietary documents for patients seeking stem cell based therapies. These documents concerning stem cell procedures will be available to both new and existing patients.
The three articles that the ISCI has published are: The ISCI Vetting Stem Cell Clinics provides a clear and concise overview of areas patients need to investigate prior to seeking stem cell therapy. The article provides information on how to evaluate claims made by the clinic, the importance of independent review of the treatments, as well as an explanation about the importance of long-term follow up. iscelli.com/vettingstemcellclinics.php
20 Questions to Ask a Physician provides critical questions patients should ask before seeking treatment. Patients are urged to read the article, which discusses how cells are removed and injected into the patients, as well as how to determine the qualification of the physicians. http://iscelli.com/ questionstoask.php
Patient Rights details patient rights and includes a thorough discussion on how patients should be treated by clinics and physicians. It also sets expectations of treatment while defining the level of care and service to be afforded to all patients. The ISCI believes patients should understand their role in a clinical study and understand there can be no guarantees. http://iscelli.com/patientsrights.php
"The ISCI has set the bar extremely high," said David Audley, CEO of the ISCI. "No other clinic has taken such a bold, public stance on patient care and safety. These documents are a powerful collection of questions and observations that range from collection and processing of cells, to outcome tracking and access to access to medical records. These are the most complete and comprehensive set of views to protect and educate patients. We believe we have set the standard for every clinic, while enshrining transparency and protecting patient safety."
About Integrative Stem Cell Institute (ISCI) The Integrative Stem Cell Institute (ISCI) is a premier provider of point-of-care, stem cell-based therapies for patients from around the world. With a state of the art laboratory housed within the Hospital Galenia in Cancun, Mexico, the ISCI combines the most advanced scientific application of stem cells with second to none medical care within the structure of adaptive clinical trials to effectively track long term outcomes and assure patient safety. More information on the Integrative Stem Cell Institute is available at www.iscelli.com
Dear Valued Members, YFRM is Our Biotech play this week. Our last 3 Biotech plays have broken records: Those 3 plays being AMBS from .005 to .19 cents and BMSN from .001 to .006 cents and ALQA from .049 to .104cents.
YFRM ~ The chart is oversold and it just formed a nice bottom Thursday and Friday, is reversing on the charts, closed above the 50 day moving average and is trading dirt cheap compared to its recent highs at .33 cents. You may want to make sure you're Liquid and Ready this weekend for Monday's trading session.
YFRM ~Recent News~
YaFarm Technologies, Inc. Recaps Major Developments
PITTSTON, ME--(Feb 19, 2013) - YaFarm Technologies, Inc. ( YFRM ) (YaFarm, or the Company) has reached several important milestones since signing the definitive agreement with The Integrative Stem Cell Institute (ISCI). YaFarm has appointed top level management for ISCI by announcing David Audley as CEO and Juan A. Castillo as Chairman of the Board of Directors. Dr. Castillo is a pioneer in regenerative medicine and has successfully treated over 250 patients using adult stem cells, while Mr. Audley successfully managed the International Cellular Medicine Society (ICMS) for nearly 4 years. Under Mr. Audley's leadership, the organization grew from 7 physicians to over 3500 members from 35 countries.
As a result of these appointments, ICSI has secured a definitive agreement with the Hospital Galenia in Cancun, Mexico to provide stem cell treatments at the medical center. Galenia is a state of the art medical facility with a staff of highly trained and globally respected medical professionals. ISCI has begun construction of a class 10,000, ISO 7 clean room for the processing of autologous, mesenchymal cells for point-of-care therapies. The ISCI lab is housed in the Hospital Galenia in Cancun, Mexico. ISCI believes that the design and construction of this category of laboratory space within a hospital setting is critical for the continued advancement of the field of regenerative medicine. In addition, ISCI has launched The International Stem Cell Practice (ISCP) to connect physicians with opportunities for education, training and collaboration in regenerative medicine, as well as international patients. Members of ISCP will work directly with ISCI in providing medical oversight and care to patients participating in clinical studies.
Last week YaFarm announced that the ISCI has submitted its complete protocols for the treatment of chronic and degenerative diseases to the Institutional Review Board (IRB) of the International Cell Surgical Society (ICSS). The IRB will study ISCI's procedures, while also reviewing the study. The studies ISCI submitted for approval will be conducted in its medical facility at the Hospital Galenia in Cancun, Mexico.
David Audley, CEO of the ISCI, said, "The ISCI has pioneered the field of cell-based regenerative medicine. We are excited about the potential for our world-class medical facility and state-of-the-art laboratory." Mr. Audley continued, "Through the ISCP, we plan to educate physicians about the field of regenerative medicine, while providing opportunities at the ISCI." YaFarm Technologies CEO Brian Hermenze stated, "The progress we have made since signing the definitive agreement with the ICSI has put us ahead of schedule. Now we have a seasoned and successful management team in place, plans for a state of the art facility, and a network of physicians who can refer patients for procedures."www.iscelli.com
